natgillin/translations-raw huggingface dataset:
A propulsion and steering arrangement according to any one of the preceding claims, wherein the at least one twist angle (a, β) decreases in aft direction to 0° within a range defined by the respective leading edge (12, 13) and the pivot axis (P) of the rudder (10; 10'). 
Raspored pogona i upravljanja prema bilo kojem od prethodnih zahtjeva, pri čemu se barem jedan torzijski kut (a, β) smanjuje u smjeru krme do 0° unutar raspona definiranog odgovarajućim vodećim rubom (12, 13) i središnjom osi (P) kormila (10; 10').
A propulsion and steering arrangement according to claim 5, wherein the rudder (10) is a full spade rudder. 
Raspored pogona i upravljanja prema zahtjevu 5, pri čemu je kormilo (10) ovješeno kormilo.
A propulsion and steering arrangement according to claim 5, wherein the rudder (10') is a semi spade rudder. 
Raspored pogona i upravljanja prema zahtjevu 5, pri čemu je kormilo (10') poluovješeno kormilo.
The bag-in-container according to claim 1, wherein the inner (21) and outer (22) layers are of different materials. 
Posuda s vrećicom unutar nje prema patentnom zahtjevu 1, naznačena time da su unutrašnji (21) i vanjski (22) slojevi od različitih materijala.
The bag-in-container according to claim 1, wherein the inner (21) and outer (22) layers are of the same material. 
Posuda s vrećicom unutar nje prema patentnom zahtjevu 1, naznačena time da su unutrašnji (21) i vanjski (22) slojevi od istog materijala.
The bag-in-container according to claim 1, wherein the inner (21) and outer (22) layers consist of a material selected from PET, PEN, PTT, PA, PP, PE, HDPE, EVOH, PGAc, PLA, and copolymers or blends thereof. 
Posuda s vrećicom unutar nje prema patentnom zahtjevu 1, naznačena time da su unutrašnji (21) i vanjski (22) slojevi od materijala izabranih od PET, PEN, PTT, PA, PP, PE, HDPE, EVOM. PGAc, PLA i kopolimera ili njihovih mješavina.
The bag-in-container according to claim 1, wherein the at least one vent (3) is in the shape of a wedge with the broad side at the level of the opening (4) thereof and getting thinner as it penetrates deeper into the vessel, until the inner and outer layers meet to form an interface. 
Posuda s vrećicom unutar nje prema patentnom zahtjevu 1, naznačena time da je barem jedan otvor (3) u obliku klina sa širokom stranom u ravnini s otvorom (4) istoga te koji se sužava kako dublje ulazi u posudu, dok se unutarnji i vanjski slojevi ne sastanu tako da oblikuju međuprostor.
The bag-in-container according to claim 1, wherein more than one vent (3) is distributed around the lip of the bag-in-container's mouth. 
Posuda s vrećicom unutar nje prema patentnom zahtjevu 1, naznačena time da je više od jedan otvor (3) raspoređen oko ruba otvora posude s vrećicom unutar nje.
The preform according to claim 7, wherein the inner (11) and outer (12) layers consist of different materials. 
Predsklop prema patentnom zahtjevu 7, naznačen time da se unutrašnji (11) i vanjski (12) slojevi sastoje od različitih materijala.
The preform according to claim 7, wherein the inner (11) and outer (12) layers consist of the same material. 
Predsklop prema patentnom zahtjevu 7, naznačen time da se unutrašnji (11) i vanjski (12) slojevi sastoje od istih materijala.
The preform according to claim 7, wherein the inner (11) and outer (12) layers consist of a material selected from PET, PEN, PTT, PA, PP, PE, HDPE, EVOH, PGAc, PLA, and copolymers or blends thereof. 
Predsklop prema patentnom zahtjevu 7, naznačen time da se unutrašnji (11) i vanjski (12) slojevi sastoje od materijala izabranih od PET, PEN, PTT, PA, PP, PE, HDPE, EVOH. PGAc, PLA i kopolimera ili njihovih mješavina.
The preform according to claim 7, wherein the at least one vent (3) is in the shape of a wedge with the broad side at the level of the opening (4) thereof and getting thinner as it penetrates deeper into the vessel, until the inner and outer layers meet to form an interface. 
Predsklop prema patentnom zahtjevu 7, naznačen time da je barem jedan otvor (3) u obliku klina sa širokom stranom u ravnini s otvorom (4) istoga te koji se sužava kako dublje ulazi u posudu, dok se unutarnji i vanjski slojevi ne sastanu tako da oblikuju međuprostor.
• providing a preform which consists of an assembly of two separate inner (11) and outer (12) preforms fitted into one another; 
• priprema predsklopa koji se sastoji od sklopa dva odvojena unutrašnjeg (11) i vanjskog (12) predsklopa umetnutih jedan u drugoga;
The method according to claim 20, wherein the at least one pin is in the shape of a wedge with the broad side at the level of where it is connected to the core's base. 
Postupak prema patentnom zahtjevu 20, naznačen time da je barem jedan šiljak u obliku klina sa širokom stranom u ravnini gdje se povezuje s osnovicom jezgre.
Power supply system according to claims 1, wherein said AC power feeds are symmetric. 
Sustav opskrbe energijom prema zahtjevu 1, gdje su spomenuti ulazi AC struje simetrični.
Power supply system according to claims 1, wherein said YD transformer constitutes a D0/Y11 vector group, the windings as a whole thus constituting a D0/Y11/Y5 vector group. 
Sustav opskrbe energijom prema zahtjevu 1, gdje spomenuti YD transformator predstavlja D0/Y11 spoj, namoti kao cjelina tako predstavljaju D0/Y11/Y5 spoj.
by reacting a compound of formula (XIV): 
reakcije spoja formule (XIV):
wherein R1, R2, G and p are as defined for formula (I) and X is a leaving group, with a compound of formula (V): wherein R3 and R4 are as defined in claim 1. 
[image] gdje R1, R2, G i p su kao što je definirano za formulu (I), a X je izlazna skupina, sa spojem formule (V): [image] gdje R3 i R4 su definirani u skladu s patentnim zahtjevom 1.
A composition suitable for control of diseases caused by phytopathogens comprising 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A method of controlling diseases on useful plants or on propagation material thereof caused by phytopathogens, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition according to claim 1 . 
Postupak za kontrolu bolesti na korisnim biljkama ili na materijalu za razmnožavanje korisnih biljaka, naznačen time da uključuje primjenu na korisne biljke, na njihov lokus ili na materijal za razmnožavanje biljke pripravka prema zahtjevu 1.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound chlorothalonil. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) [image] pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound bixafen. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) [image] pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A pharmaceutical composition comprising fesoterodine, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable stabilizer, wherein said stabilizer is selected from the group consisting of xylitol, sorbitol, polydextrose, isomalt, dextrose and combinations thereof. 
Farmaceutski sastav koji sadrži fesoterodin, ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv stabilizator, naznačen time da je navedeni stabilizator odabran iz skupine koja se sastoji od ksilitola, sorbitola, polidekstroze, izomalta, dekstroze i njihovih kombinacija.
The pharmaceutical composition according to claim 1, wherein said stabilizer is xylitol, sorbitol or polydextrose. 
Farmaceutski sastav prema patentnom zahtjevu 1, naznačen time da je navedeni stabilizator ksilitol, sorbitol ili polidekstroza.
The pharmaceutical composition according to claim 1, wherein said stabilizer is xylitol. 
Farmaceutski sastav prema patentnom zahtjevu 1, naznačen time da je navedeni stabilizator ksilitol.
A pharmaceutical composition according to claim 5, wherein the fesoterodine salt is a salt of a di- or tricarboxylic acid, or of a partially hydrogenated di- or tricarboxylic acid. 
Farmaceutski sastav prema patentnom zahtjevu 5, naznačen time da je sol fesoterodina sol di- ili trikarboksilne kiseline, ili djelom hidrogenirane di- ili trikarboksilne kiseline.
A pharmaceutical composition according to claim 7, which is in unit dosage form and characterized in that fesoterodine hydrogen fumarate is present in an amount of between 0.5 and 12 mg per dosage unit. 
Farmaceutski sastav prema patentnom zahtjevu 7, koji je u obliku jediničnog doziranja naznačen time da je hidrogenfumarat fesoterodina prisutan u iznosu između 0,5 i 12 mg po jedinici za doziranje.
A pharmaceutical composition according to anyone of the preceding claims, which is obtainable by a method involving at least one granulation step. 
Farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se dobiva metodom koja uključuje najmanje jadan korak granulacije.
A pharmaceutical composition according to claim 9, wherein the granulation is wet granulation. 
Farmaceutski sastav prema patentnom zahtjevu 9, naznačen time da je granulacija vlažna granulacija.
A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition further comprises a sustained release agent. 
Farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da farmaceutski sastav nadalje sadrži sredstvo za produljeno oslobađanje.
A pharmaceutical composition according to claim 12, wherein the sustained release agent is a cellulose ether or ester or a mixture thereof. 
Farmaceutski sastav prema patentnom zahtjevu 12, naznačen time da je sredstvo za produljeno oslobađanje celulozni eter ili ester ili njihova mješavina.
A pharmaceutical composition according to claim 13, wherein the sustained release agent is hydroxypropylmethylcellulose. 
Farmaceutski sastav prema patentnom zahtjevu 13, naznačen time da je sredstvo za produljeno oslobađanje hidroksipropilmetilceluloza.
A pharmaceutical composition according to any one of claims 12 to 14, wherein the sustained release agent is contained in an amount of 20-80% [w/w], preferably 25-65%, more preferably 30-65%, and even more preferably 35-55% [w/w] based on the total composition. 
Farmaceutski sastav prema bilo kojem patentnom zahtjevu od 12 do 14, naznačen time da je navedeno sredstvo za produljeno oslobađanje sadržano u iznosu od 20-80% [po težini], poželjno 25-65%, poželjnije 30-65%, i još poželjnije 35-55% [po težini] u odnosu na cjelokupni sastav.
A pharmaceutical composition according to claim 1 comprising: 
Farmaceutski sastav prema patentnom zahtjevu 1, naznačen time da sadrži:
20-40% [w/w] of a mixture comprising 45-80% (w/w) lactose monohydrate and 55-20% (w/w) microcrystalline cellulose; 
20-40% [po težini] mješavine koja sadrži 45-80% (po težini) laktoze monohidrata i 55-20% (po težini) mikrokristalne celuloze;
20-30 mg of HPMC having a nominal viscosity of about 4,000 mPa·s when dissolved about 2% by weight) in water 
20-30 mg HPMC-a (hidroksipropilmetilceluloze) nominalne viskoznosti od oko 4.000 mPa·s kada je otopljen (oko 2% po težini) u vodi
The pharmaceutical composition for use according to claim 20, wherein overactive bladder is associated with symptoms selected from the group consisting of urinary incontinence, urinary urge incontinence, imperative urinary urge, and/or increased urinary frequency. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 20, naznačen time da je pretjerano aktivni mokraćni mjehur povezan sa simptomima odabranim iz skupine koja se sastoji od urinarne inkontinencije, urgentne urinarne inkontinencije, imperativnog urinarnog nagona i/ili povećane učestalosti uriniranja.
Use of a compound according to claim 1 in the manufacture of a medicament for use in the treatment of an autoimmune or inflammatory disease or condition. 
Uporaba spoja prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za uporabu u liječenju autoimune ili upalne bolesti ili stanja.
Use of a compound according to claim 1 in the manufacture of a medicament for use in the treatment of HIV infection or AIDS. 
Uporaba spoja prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za uporabu u liječenju HIV infekcije ili AIDS-a.
Use of a compound according to claim 1 in combination with one or more agents selected from: methotrexate, an anti-TNF agent, an anti-IL-1 agent, a nucleoside or non-nucleoside reverse transcriptase inhibitor, an HIV protease inhibitor, fusion inhibitor and antiretroviral agent in the manufacturer of a medicament for the treatment of an inflammatory or autimmune disease or condition or HIV or AIDS. 
Uporaba spoja prema zahtjevu 1, naznačena time, da se koristi u kombinaciji s jednim ili više pomoćnih sredstava odabranih od: metotreksata, anti-TNF agensa, anti-IL-1 agensa, inhibitora nukleozidne ili ne-nukleozidne reverzibilne transkriptaze, inhibitora HIV proteaze, inhibitora fuzije i antiretrovirusnog agensa, za proizvodnju lijeka za liječenje upalne ili autoimune bolesti ili stanja ili HIV-a ili AIDS-a.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.